Baxter International Inc.
NYSE:BAXMedical - Instruments & Supplies
-$1.07 today
- Market cap
- $13.53B
- Beta
- 0.64
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.13
- Dividend yield
- 1.03%
Volume 4.01M
Average 7.62M
BAX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Baxter International Inc.NYSE: BAX
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $735M rose 2.4% year over year, ahead of the -0.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at -2.3% a year.
Context
- Selling, general & admin amounted to 25.7% of revenue in FY2025, down 2.2 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 11 analysts of $3.2B (+10.6%) for the fiscal year ending Dec 2026, a step up from the -2.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $735M+1.0% QoQ
- Last fiscal yearDec 2025
- $2.89B-2.6% YoY
- LTMJun 2026
- $2.93B-0.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +2.4% | +12.0% | +9.6 pp |
| 1 year | -2.6% | +10.6% | +13.2 pp |
| 3-year CAGR | -2.3% | +4.9% | +7.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 2.89B USD
- Year-over-year change
- -2.6%
- 4-year CAGR
- +0.4%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.89B | -2.6% |
| FY2024 | 2024-12-31 | 2.97B | +0.5% |
| FY2023 | 2023-12-31 | 2.95B | -4.6% |
| FY2022 | 2022-12-31 | 3.1B | +8.9% |
| FY2021 | 2021-12-31 | 2.85B | — |
Selling, General & Admin vs competitors
How BAX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.1% is the 3rd highest of 5, against a peer median of +0.8%.
- Selling, general & admin amounts to 25.6% of revenue for BAX, versus a peer median of 21.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | €2.98B EUR | -5.2% | -1.5% | 15.3% | |
| LTM Jun 2026 | $2.93B USD | -0.1% | -2.3% | 25.6% | |
| LTM Jun 2026 | $1.73B USD | +8.6% | +7.3% | 12.4% | |
| LTM Jun 2026 | $615.07M USD | -3.6% | +0.9% | 28.5% | |
| LTM Mar 2026 | $67.04M USD | +5.2% | +6.1% | 47.1% | |
| Peer median (excluding BAX) | — | +0.8% | +3.5% | 21.9% | |
Competitors are the stored peer set for BAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.15B | 10.06B | 10.36B | 10.64B | 11.24B |
| Cost of Revenue | 7.43B | 6.51B | 6.21B | 6.65B | 7.87B |
| Gross Profit | 4.72B | 3.55B | 4.15B | 3.98B | 3.38B |
| Gross Margin | 38.9% | 35.3% | 40.1% | 37.5% | 30.1% |
| Research & Development | 531M | 450M | 518M | 590M | 518M |
| Selling, General & Admin | 2.85B | 3.1B | 2.95B | 2.97B | 2.89B |
| Operating Expenses | 3.37B | 6.39B | 3.44B | 3.97B | 3.69B |
| Depreciation & Amortization | 867M | 1.07B | 984M | 997M | 981M |
| EBITDA | 2.19B | (1.76B) | 1.73B | 1.12B | 766M |
| EBITDA Margin | 18.0% | -17.5% | 16.7% | 10.5% | 6.8% |
| Operating Income | 1.35B | (2.85B) | 707M | 14M | (308M) |
| Operating Margin | 11.1% | -28.3% | 6.8% | 0.1% | -2.7% |
| Interest Income | 14M | 19M | 69M | 67M | 52M |
| Interest Expense | 207M | 413M | 508M | 408M | 290M |
| Other Income / Expenses | (234M) | (403M) | (465M) | (303M) | (197M) |
| Income Before Tax | 1.12B | (3.25B) | 242M | (289M) | (505M) |
| Pre-Tax Margin | 9.2% | -32.3% | 2.3% | -2.7% | -4.5% |
| Income Tax Expense | 83M | (135M) | 61M | 37M | 395M |
| Net Income | 1.28B | (2.43B) | 2.66B | (649M) | (957M) |
| Net Margin | 10.6% | -24.2% | 25.6% | -6.1% | -8.5% |
| EPS (Basic) | 2.56 | (4.83) | 5.25 | (1.27) | (1.75) |
| EPS (Diluted) | 2.53 | (4.83) | 5.23 | (1.27) | (1.75) |
| Weighted Avg Shares | 502M | 504M | 506M | 510M | 513M |
| Weighted Avg Shares (Diluted) | 508M | 504M | 506M | 510M | 513M |
Baxter International Inc.
NYSE:BAX
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.